Unknown PHASE1 INTERVENTIONAL 1-arm NCT02933775

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

Autologous T Cells With a Chimeric Antigen Receptor in Patients With CD19-positive Malignant B Cell Leukemia and Lymphoma

Sponsor: CARsgen Therapeutics Co., Ltd.

Conditions CD19 Positive Malignant B-cell Leukemia and Lymphoma

Interventions CAR-CD19 T cells Cyclophosphamide Fludarabine

Updated 6 times since 2017 Last updated: Oct 13, 2016 Started: Oct 31, 2016 Primary completion: Apr 30, 2018 Completion: Jan 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates CD19 Positive Malignant B-cell Leukemia and Lymphoma and is currently ongoing. CARsgen Therapeutics Co., Ltd. leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2021 — Mar 2022 [monthly]

Unknown Status PHASE1
Feb 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CARsgen Therapeutics Co., Ltd.
RenJi Hospital

Data source: RenJi Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China